A novel antibiotic linked to rare reports of severe liver problems, including several deaths, will be subjected to new scrutiny by federal health advisers, according to a document released this week.

The Food and Drug Administration has asked a joint panel of outside experts to discuss the overall risks and benefits of the antibiotic Ketek during a Dec. 14-15 meeting, according to a federal notice.